Weiss Ratings Reiterates Sell (E+) Rating for InterCure (NASDAQ:INCR)

InterCure (NASDAQ:INCRGet Free Report)‘s stock had its “sell (e+)” rating reaffirmed by Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

InterCure Price Performance

Shares of INCR stock opened at $1.61 on Wednesday. InterCure has a 1-year low of $1.17 and a 1-year high of $1.87. The firm has a fifty day moving average of $1.57 and a two-hundred day moving average of $1.51.

About InterCure

(Get Free Report)

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.

Featured Articles

Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.